Comparison

GHK-Cu vs
KPV

Two different three-amino-acid peptides. Their identities, study records and regulatory records do not support a verdict about which is better.

Short answerCompound research · 6 min read · Updated 21 Nov 2026

GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine; KPV is Lys-Pro-Val, the C-terminal end of α-MSH. GHK-Cu has small human skin studies, among them a randomised one with 13 completers (T1); KPV has cell and mouse studies (T4, T3), and FDA staff identified no human exposure data for it. WADA names neither, and says an unnamed peptide “may still be prohibited”.

Key takeaways

  • GHK-Cu is a copper complex; KPV is the Lys-Pro-Val sequence.
  • A small randomized human study of GHK-Cu had 13 completers in 2006; KPV research cited here is in cells and mice.
  • FDA staff proposed not adding KPV to the 503A bulks list (July 2026); HHS records that its advisory committee voted in favour, and HHS’s October 2026 draft policy, which “is not binding”, names KPV.
  • Neither name appears on WADA’s 2026 or 2027 List; WADA says a peptide not specifically named “may still be prohibited”.

01GHK-Cu vs KPV in one table

A side-by-side summary. Regulatory records were checked for this draft on 21 November 2026; unresolved points are labelled.

QuestionGHK-CuKPV
IdentityCopper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK)Tripeptide Lys-Pro-Val, also known as α-MSH(11–13)
Evidence tiers in studies cited hereOne small randomised human skin study (T1); GHK-Cu’s animal (T3) and cell (T4) studies are on its guideHuman cell studies (T4) and animal models (T3); these are not evidence of an effect in people
Human dataMiller et al. (2006): randomised study; 13 participants completed. Among the measures: erythema and evaluator ratings of skin appearance. Material sold online is not the formulation tested.FDA reported no identified clinical studies or human exposure data for KPV in its July 2026 briefing.
United StatesFDA’s list of substances nominated for compounding (updated 14 May 2026) places GHK-Cu, for certain routes of administration only, in Category 1, bulk drug substances under evaluation; it is not in HHS’s October 2026 draft policy. The FDA records, dated: GHK-Cu research guide.FDA staff proposed not adding KPV to the 503A bulks list (July 2026 briefing); HHS records that the advisory committee voted in favour. HHS’s October 2026 draft policy, which “is not binding”, names KPV.
United KingdomThe emc medicines database returned no results for GHK, copper tripeptide or prezatide (21 Nov 2026); it is not the full UK registerThe emc database returned no results for KPV (21 Nov 2026)
AustraliaThe TGA says that “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” GHK-Cu has no entry by name in the Poisons Standard October 2026, which has group entries for copper compounds; we draw no scheduling conclusion of our own.For KPV, the TGA statement on the left; KPV has no entry by name in the Poisons Standard October 2026, and we draw no scheduling conclusion of our own.
WADA, 2026 and 2027 ListsNot named. WADA says a peptide not specifically named “may still be prohibited”Not named, as on the left

02How are GHK-Cu and KPV different in identity?

If you searched “kpv vs ghk cu,” the first distinction is chemical identity. Both names refer to three-amino-acid peptides, but GHK-Cu also includes copper(II). KPV is the Lys-Pro-Val sequence at the C-terminal end of α-MSH; it is not a copper complex.

GHK-Cu

Three amino acids complexed with copper(II). The sequence is glycyl-L-histidyl-L-lysine.

KPV

Three amino acids in the order Lys-Pro-Val; it is also called α-MSH(11–13).

Names alone do not establish what a particular sample contains. To assess an identity result, see how to read a COA.

03What models have researchers studied?

These are study designs, not evidence that either peptide has an effect in people. T3 means animal evidence; T4 means cell or mechanistic evidence.

Peptide and studyModelWhat researchers measuredEvidence tier
KPV, Dalmasso et al. (2008)Human intestinal epithelial cell lines, a human T-cell line, and two mouse modelsCell signalling, cytokine measures, and tissue histologyT4 and T3; not evidence of an effect in people
KPV, Elliott et al. (2004)Human keratinocyte cellsIntracellular signalling responsesT4; not evidence of an effect in people
GHK-Cu, Miller et al. (2006)Randomized human study; 13 participants completedErythema and evaluator ratings of wrinkles and skin appearanceT1, small; material sold online is not the formulation tested

The models and measures differ. They do not create a direct comparison between GHK-Cu and KPV, and results from one peptide cannot be assigned to the other.

04What does the human evidence show?

For KPV, FDA’s July 2026 briefing says the agency had not identified clinical studies or human exposure data. That is a dated search finding, not proof that no such data could ever exist. The cell and mouse papers cited above do not answer how KPV behaves in people.

For GHK-Cu, Miller and colleagues published a small randomized human study in 2006. Thirteen participants completed it. The study recorded erythema and evaluator ratings after a skin-resurfacing procedure. Those design details say what was studied, not whether GHK-Cu had an effect, and material sold online is not the formulation tested.

For a closer look at the GHK-Cu record and its limits, read the GHK-Cu research guide. The evidence grades page explains how we label study types.

05What do the regulatory records not settle?

The country rows in the table describe specific documents, not a single worldwide legal status. For the United States, FDA staff’s KPV recommendation concerns a compounding list. It does not by itself resolve every product or legal question. In the UK, the emc medicines database returned no results for either name (21 November 2026); it is not the full UK register.

In Australia, the October 2026 Poisons Standard does not name GHK-Cu or KPV. It has group entries for copper compounds, but this page does not decide whether those entries apply to GHK-Cu. We draw no scheduling conclusion from the name searches.

Neither GHK-Cu nor KPV is named in WADA’s 2026 List. The List also has broader classes: an unnamed substance may still fall within a class. Absence by name is not a conclusion that either peptide is permitted in sport.

  • We do not know whether results from cell or animal models predict an effect in people.
  • FDA reported no identified human exposure data for KPV in its July 2026 briefing; its human safety profile remains unknown in that document.
  • This comparison does not determine the status of a specific finished product in the United States, United Kingdom or Australia.
  • A study of one peptide does not establish a result for the other.

This is a plain-English summary of public studies and documents, checked on 21 November 2026. It is not legal or medical advice.

RefSources

  1. National Center for Biotechnology Information. GHK-Cu, PubChem CID 165429100. Compound record, read 21 Nov 2026. pubchem.ncbi.nlm.nih.gov/compound/N2-_N-glycyl-L-histidyl_-L…
  2. National Center for Biotechnology Information. L-lysyl-L-prolyl-L-valine acetate, PubChem CID 90474670. Compound record, read 21 Nov 2026. pubchem.ncbi.nlm.nih.gov/compound/90474670
  3. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: KPV-related bulk drug substances. Advisory committee briefing, 2026 (pp. 26, 28–29); read 21 Nov 2026. www.fda.gov/media/193346/download
  4. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al. [KPV study in cell lines and mouse models]. Gastroenterology, 2008;134(1):166–178. PMID 18061177. pubmed.ncbi.nlm.nih.gov/18061177/
  5. Elliott RJ, Szabo M, Wagner MJ, et al. [KPV and signalling in human keratinocyte cells]. Journal of Investigative Dermatology, 2004;122(4):1010–1019. PMID 15102092. pubmed.ncbi.nlm.nih.gov/15102092/
  6. Miller JH, et al. [Randomized human study of GHK-Cu in a post-resurfacing skin-care regimen]. Archives of Facial Plastic Surgery, 2006;8:252–259. PMID 16847171. pubmed.ncbi.nlm.nih.gov/16847171/
  7. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327). Federal Register of Legislation; commenced 1 Oct 2026; text read 21 Nov 2026. www.legislation.gov.au/F2026L01327/asmade/2026-09-30/text/or…
  8. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3). List updated 14 May 2026; read 21 Nov 2026. www.fda.gov/media/94155/download
  9. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (draft), Appendix B; Federal Register notice FR Doc. 2026-22192, 30 Oct 2026. Appendix read on the Internet Archive capture of 15 Nov 2026, the newest readable one (hhs.gov returned 403 to our tools). web.archive.org/web/20261115103435/https://www.hhs.gov/sites…
  10. Electronic medicines compendium (emc). Searches for GHK, copper tripeptide, prezatide and KPV: “No search results” for each (control search, somatropin, returned results). Database searches, 21 Nov 2026. www.medicines.org.uk/emc/search?q=KPV
  11. Therapeutic Goods Administration. Peptide products. Topic page, last updated 23 Sep 2026; read on the Internet Archive capture of 5 Nov 2026, the newest (tga.gov.au did not respond to our tools). web.archive.org/web/20261105200754/https://www.tga.gov.au/re…
  12. World Anti-Doping Agency. Prohibited List 2027 (in force 1 Jan 2027) and the 2027 summary of major modifications and explanatory notes, S0. International Standard and explanatory note; read 21 Nov 2026. www.wada-ama.org/sites/default/files/2026-09/2027_list_expla…
  13. World Anti-Doping Agency. 2026 Prohibited List. International Standard, in force 1 Jan 2026; read 21 Nov 2026. www.wada-ama.org/sites/default/files/2025-09/2026list_en_fin…

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

Are GHK-Cu and KPV the same peptide?

No. GHK-Cu is a copper(II) complex of glycyl-L-histidyl-L-lysine. KPV is Lys-Pro-Val, the C-terminal tripeptide of α-MSH.

What human data did FDA identify for KPV?

In its July 2026 briefing, FDA said it had not identified clinical studies or human exposure data for KPV. The cell and animal studies cited here are not human studies.

What did the 2006 GHK-Cu study measure?

Miller and colleagues reported a randomized human study with 13 completers. It recorded erythema and evaluator ratings of wrinkles and skin appearance after a skin-resurfacing procedure.

Do WADA’s Lists name either peptide?

Neither name appears on the 2026 or 2027 List. WADA says a peptide not specifically named “may still be prohibited”.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page